Pharma
AbbVie joins the weight loss race
In a $350m deal, AbbVie bought a Danish weight loss drug in Phase 1 clinical trials.
In a $350m deal, AbbVie bought a Danish weight loss drug in Phase 1 clinical trials.
Advocacy group and bipartisan letters urged the FDA to take action and pull the ad from running during Sunday’s game.
While both drugs are GLP-1s, they have different active ingredients.
The administration proposed allowing Medicare and Medicaid to cover the drugs for weight loss, not just diabetes and cardiovascular disease.
From GLP-1s to AI, leaders share their thoughts.
From GLP-1s to PBMs, these execs give their thoughts.
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.